Medical devices made from poly(dimethylsiloxane) (PDMS)-based silicone implants have been broadly used owing to their inert properties, biocompatibility, and low toxicity. However, long-term implantation is usually associated with complications, such as capsular contracture due to excessive local inflammatory response, subsequently requiring implant removal. Therefore, modification of the silicone surface to reduce a risk of capsular contracture has attracted increasing attention. Human adipose-derived stem cells (hASCs) are known to provide potentially therapeutic applications for tissue engineering, regenerative medicine, and reconstructive surgery. Herein, hASCs coating on a PDMS (hASC-PDMS) or itaconic acid (IA)-conjugated PDMS (hASC-IA-PDMS) surface is examined to determine its biocompatibility for reducing capsular contracture on the PDMS surface. In vitro cell cytotoxicity evaluation showed that hASCs on IA-PDMS exhibit higher cell viability than hASCs on PDMS. A lower release of proinflammatory cytokines is observed in hASC-PDMS and hASC-IA-PDMS compared to the cells on plate. Multiple factors, including in vivo mRNA expression levels of cytokines related to fibrosis; number of inflammatory cells; number of macrophages and myofibroblasts; capsule thickness; and collagen density following implantation in rats for 60 days, indicate that incorporated coating hASCs on PDMSs most effectively reduces capsular contracture. This study demonstrates the potential of hASCs coating for the modification of PDMS surfaces in enhancing surface biocompatibility for reducing capsular contracture of PDMS-based medical devices.

中文翻译：

---

表面改性硅胶植入物上的人体脂肪干细胞减少包膜挛缩形成的评估


由聚二甲基硅氧烷（PDMS）基有机硅植入物制成的医疗器械由于其惰性、生物相容性和低毒性而被广泛使用。然而，长期植入通常会带来并发症，例如由于局部过度炎症反应导致包膜挛缩，随后需要移除植入物。因此，对有机硅表面进行改性以降低包膜挛缩的风险引起了越来越多的关注。众所周知，人类脂肪干细胞 (hASC) 可为组织工程、再生医学和重建手术提供潜在的治疗应用。在此，检查 PDMS (hASC-PDMS) 或衣康酸 (IA) 缀合的 PDMS (hASC-IA-PDMS) 表面上的 hASC 涂层，以确定其减少 PDMS 表面包膜挛缩的生物相容性。体外细胞毒性评估表明，IA-PDMS 上的 hASC 比 PDMS 上的 hASC 表现出更高的细胞活力。与平板上的细胞相比，在 hASC-PDMS 和 hASC-IA-PDMS 中观察到促炎细胞因子的释放较低。多种因素，包括与纤维化相关的细胞因子的体内mRNA表达水平；炎症细胞的数量；巨噬细胞和肌成纤维细胞的数量；胶囊厚度；植入大鼠体内 60 天后的胶原蛋白密度和胶原蛋白密度表明，在 PDMS 上掺入涂层 hASC 最有效地减少包膜挛缩。这项研究证明了 hASC 涂层在修饰 PDMS 表面、增强表面生物相容性、减少基于 PDMS 的医疗器械的包膜挛缩方面的潜力。